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2Abstract
Background: Given the rapid increase in e-cigarette (EC) popularity and paucity of longitudinal health-
related data associated with this, there is an urgent need to assess the potential risks of long-term EC use.
Objective: To compare exposure to nicotine, tobacco-related carcinogens and toxicants among cigarette-
only smokers, and smokers and ex-smokers with long-term EC use or with use of nicotine replacement 
therapy (NRT; a product with known safety profile).
Design: Cross-sectional study.
Setting: United Kingdom.
Participants: Five groups were purposively recruited: (1) cigarette-only users, (2) ex-smokers with long-
term (≥6 months) EC-only or (3) NRT-only use, and (4) long-term dual cigarette-EC or (5) dual cigarette-
NRT users (N=36-37 per group, total N=181).
Measurements: Socio-demographic and smoking characteristics were assessed; participants provided urine 
and saliva samples, analysed for biomarkers of nicotine, tobacco-specific nitrosamines (TSNAs) and volatile 
organic compounds (VOCs).
Results: After controlling for confounders, there were no clear group differences in salivary or urinary 
biomarkers of nicotine intake. EC-only and NRT-only users had significantly lower metabolite levels for 
TSNAs (including the carcinogenic metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, NNAL) and 
for VOCs (including metabolites of the toxicants acrolein, acrylamide, acrylonitrile, 1,3-butadiene, ethylene 
oxide) compared with cigarette-only, dual cigarette-EC or cigarette-NRT users. EC-only users had
significantly lower NNAL levels than all other groups. Cigarette-only, dual cigarette-NRT and cigarette-EC 
users had largely similar levels of TSNA and VOC metabolites.
Limitations: Cross-sectional design with self-selected sample.
Conclusions: Ex-smokers with long-term EC-only or NRT-only use may achieve approximately similar 
nicotine intake to cigarette-only smokers but results were variable. Long-term NRT-only and EC-only use, 
but not dual use with cigarettes, is associated with substantially reduced levels of measured carcinogens and 
toxicants relative to cigarette-only smoking.
3Primary source of funding: Cancer Research UK (C27061/A16929).
Key words: electronic cigarettes, nicotine replacement therapy, biomarkers, nicotine, TSNA, VOC, 
carcinogens, toxicants, harm reduction, long-term use, tobacco control
4Introduction
E-cigarettes (EC) are increasingly popular devices (1) that produce an aerosol by heating a solvent (e-
liquid) usually containing nicotine through a battery-powered heating element. Unlike smoked tobacco, 
nicotine can therefore be delivered to the respiratory tract without combustion (2). Despite this possible 
advantage, health concerns about EC remain regarding potential cytotoxicity, delivery of carcinogens (3), 
including carbonyls (4, 5), tobacco-specific N-nitrosamines (TSNAs, (6)) and heavy metals (4), effects on 
cardiovascular and respiratory function and inflammation (7) and nicotine delivery (8). Data on the effects of 
long-term EC use are needed to assess their risks and potential effectiveness accurately and to inform health 
professionals encountering EC users (9).
To date, most studies have looked at toxicant concentrations in EC liquids or aerosol (e.g. (4, 6)) 
using cell-line or animal models (e.g. (7)). However, this may not provide accurate information as user 
characteristics, together with device characteristics and their interaction, determine actual body-level 
exposure, and thus potential health consequences (10). Three studies that have assessed body-level exposure 
found lower levels for carcinogens, including TSNAs, in recent ex-smokers using EC compared with a 
historic sample of smokers (11), and reductions in toxicants over a two- or four-week period in smokers 
switching to EC with or without concurrent smoking (12, 13). However, none of the studies involved long-
term users, which is important given observed learning effects in EC use (14) (15), or included real-world 
control groups to reduce the risk of confounding when interpreting results of observational studies.
Nicotine replacement therapy (NRT) users would be an appropriate control. Dual use with cigarettes 
of either EC or NRT is common, and there is some long-term use of both (16, 17). Both have been advocated 
as harm reduction products used to reduce risks associated with combustible tobacco use (18). However, 
unlike EC, the NRT safety profile is well established (e.g. (19)) and NRT effectiveness for smoking cessation 
through intial partial (20) or complete substitution (21) has been demonstrated. NRT is therefore
5recommended as a harm reduction strategy in several countries (22).
While longitudinal cohort studies and randomised controlled trials will provide the best data to answer 
questions concerning the safety and efficacy for smoking cessation of EC use, these designs are time- and 
resource-intensive. In the absence of long-term data, a more pragmatic approach is to compare smokers and 
ex-smokers as a function of EC use in real life settings. This study aimed to address the gap in the existing 
literature by measuring biomarker levels in long-term users of EC compared with an appropriate control, 
NRT users. Specifically, this study assessed whether long-term EC-only, NRT-only, dual cigarette-EC or 
dual cigarette-NRT use is associated with differences in metabolites of a) nicotine; b) TSNAs and c) volatile 
organic compounds (VOC) compared with cigarette-only smokers.
6Methods
Study design and procedure
This cross-sectional study, carried out in January–June 2014 in London, UK sought to evaluate the 
range of toxicant levels measured in smokers and ex-smokers with or without concurrent long-term use of 
EC or NRT. The study methodology has been described elsewhere (23). Briefly, participants visited the 
laboratory for a single session, lasting 30 minutes, after abstaining from eating, drinking or using cigarettes or 
nicotine products an hour before their visit to standardise assessment. At the laboratory, after providing 
written consent, participants completed a short questionnaire assessing socio-demographic, smoking and 
product use characteristics and provided breath, saliva and urine samples. Expired air was assessed for carbon 
monoxide (CO) with a breathalyser (Micro IV Smokerlyzer, Bedfont Scientific, Kent, England). In addition, 
two saliva samples were collected with sterile dental rolls (Salivette®, Sarstedt Ltd, Leicester, England) 
which participants were asked to gently chew for about two minutes or until saturated. Urine was collected in 
a sealable, sterilised cup by participants on site and transferred by staff into cryovials. Urine and saliva 
samples were then kept frozen at -20°C until shipment in dry ice for analysis to laboratories at Roswell Park 
Cancer Institute (RPCI) and the U.S. Centers for Disease Control and Prevention (CDC). All participants 
were reimbursed for time and travel (£25). The study was approved by the University College London Ethics 
Committee (Project ID 0483/002).
Participants
Participants were purposively recruited in the greater London area using a variety of methods to 
increase sample diversity, including newspapers and online adverts, posters in pharmacies, and the use of 
marketing companies. Participants had to be ever smokers and were eligible to take part if they fulfilled the 
following inclusion criteria: current smokers had to smoke an average of five or more cigarettes per day for at 
least six months, and ex-smokers had to have stopped using tobacco products (including cigarettes, 
waterpipe, cigars, smokeless products such as snus or chewing tobacco) for at least six months. Because this 
7study sought to evaluate the impact of long-term use of non-combustible nicotine delivery devices (NRT and 
EC), smokers (i.e. dual cigarette-EC or cigarette-NRT users) and ex-smokers (i.e. EC-only or NRT-only 
users) had to have been using these products at least weekly for six or more months (users of nicotine-free 
products, e.g. using e-liquid without nicotine, were excluded). In practice, however, participants used 
products daily as indicated by latency to last product use across groups (Cigarettes-only: 1.4h; Dual cigarette-
NRT: 4.3h; Dual cigarette-EC: 1.3h; NRT-only: 24h; EC-only: 5.4h). Product use was verified by asking 
participants to bring in the NRT or EC that they were currently using, and smoking status was verified with 
CO readings (10 ppm cut-off (24)). Participants who used both NRT and EC were excluded as were those 
below 18 years of age, pregnant or with a history of heart or lung disease or bleeding gums, illness, or an 
active infection within 24 hours of their scheduled appointment. 
Measures
Biomarkers of exposure
Level of nicotine exposure was determined to assess effectiveness of nicotine-delivery products using 
two different methodologies. Saliva samples were analysed for nicotine, and its major metabolite cotinine, 
using established gas chromatography methodology (25, 26). Urine samples were analysed for main nicotine 
metabolites to derive total nicotine equivalents and for minor tobacco alkaloids using validated tandem mass 
spectrometry methodology (27, 28).
Levels of urinary TSNA and VOC metabolites were determined using liquid chromatography 
atmospheric pressure ionization tandem mass spectrometry (29) and ultra-high performance liquid 
chromatography coupled with electrospray ionisation and tandem mass spectrometry (30), respectively, to 
assess the potential risk of nicotine-delivery products. While a comprehensive battery of metabolites was 
assessed (see Table S1), we focus here on well-established metabolites of compounds that are known to 
contribute significantly to smoking-related toxicological and carcinogenic risks (31-39) (see Table 1). All 
analyses of urinary and salivary biomarkers were carried out by the CDC and RPCI, respectively.
8Covariates
Socio-demographic characteristics (age, sex, ethnicity, education, marital status) were assessed in 
addition to self-reported recently resolved physical illness (chest infection, cold/flu, sore throat, fever), 
subjective well-being (happiness and satisfaction, both assessed with established single item measures (40)) 
and C-reactive protein (CRP) as a marker of inflammation (and thus potential health problems), measured in 
saliva and analysed with the ELISA method by Salimetrics Europe Ltd, UK (41). Smoking characteristics 
assessed included current and past daily cigarette consumption as a measure of dependence for smokers and 
ex-smokers, respectively, age at which participants had started smoking and the proportion of family or 
friends who smoke to gauge environmental tobacco smoke exposure.
Analysis
As this was a cross-sectional study, exposure biomarkers including metabolites of known tobacco-
related carcinogens and toxicants were used as proxies for future disease risk. Previous research on the 
association of the carcinogenic metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) with lung 
cancer suggests that medium-large reductions in NNAL levels (Cohen’s f=0.25-0.40) would result in an 
appreciable reduction in risk (42) and could thus be considered clinically meaningful in magnitude and 
warrant further investigation (43). A priori power calculation showed that 180 participants (36 per group) 
would provide 90% power to detect between-group differences of a medium effect size (Cohen’s f=0.3) in 
NNAL levels when comparing five groups, using analysis of variance (44). However, this calculation did not 
account for multiple outcomes being tested, and based on 35 biomarker outcomes reported here, power to 
detect such an effect size across all biomarkers would have been reduced to 54%. The sample size therefore 
only provided sufficient power (≥80%) to detect effects at the upper range of the estimate (Cohen’s f≥ 0.36) 
when accounting for multiple comparisons.
Analyses were conducted with SPSS Version 22.0. In initial analysis of group differences on 
covariates, one-way ANOVAs were used for continuous and chi-square analysis for categorical covariates, 
9respectively. Prior to the main analysis, urinary metabolites were standardised algebraically to account for 
individual differences in urine concentration by dividing metabolite data by the ratio of observed to age-, sex-, 
and ethnicity-adjusted creatinine values and creatinine (measured by standard colorimetric method at RCPI) 
was also included as covariate in analysis (see Method 7 in 45). Due to non-normal distribution of data, 
generalised linear models with a log link and gamma distribution were used to assess group differences in 
outcome measures, adjusted for all covariates and latency to product use. B coefficients were exponentiated 
to obtain percent change in biomarker levels in all groups compared with cigarette-only smokers. For pre-
specified tests of main effects of group, Type I errors were controlled using the false discovery rate (46) 
separately for socio-demographic comparisons (N=13) and biomarker comparisons (N=35). Where overall 
omnibus effects were considered significant, the Sidak correction was used in post-hoc analysis to determine 
between which (if any) groups differences persisted. Biomarker values below the limit of detection (LOD) 
were imputed using standard methodology (LOD divided by square root of 2 (47)), and biomarkers with 50% 
or more of values below the LOD were not analysed.
Role of funding source
This work was supported by Cancer Research UK (C27061/A16929) with additional funding from 
Cancer Research UK (C1417/A14135; C36048/A11654). JB’s post is funded by a fellowship from the 
Society for the Study of Addiction and CRUK also provide support (C1417/A7972; C44576/A19501). AM 
and RW are part of the UK Centre for Tobacco and Alcohol Studies, a UK Clinical Research Collaboration 
Public Health Research: Centre of Excellence. Funding from the Medical Research Council, British Heart 
Foundation, Cancer Research UK, Economic and Social Research Council and the National Institute for 
Health Research under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged 
(MR/K023195/1). MLG was supported by the National Institute on Drug Abuse (NIDA) and the National 
Cancer Institute (NCI) of the National Institutes of Health under Award Number R01DA037446 and P30 
CA016056, respectively, and by an award from Roswell Park Alliance Foundation. The content is solely the 
responsibility of the authors and does not necessarily represent the official views of the National Institutes of 
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collection, data analysis, data interpretation, or writing of the report. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for publication.
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Results
Overall, participants were relatively young, mainly male, white, had at least a high school education, 
and about half were single (see Table 2). On average, participants had started smoking in their late teens, 
smoking nearly one pack a day, with a substantial proportion (16%-51%) of their family or friends smoking. 
Salivary CRP levels were within the range observed for healthy adults (0.05-64.3 μg/L) (48) and reported 
well-being levels comparable to that of representative population samples (40). There were some group 
differences: the proportion of females varied from 19.4% in EC-only users to 61.1% in dual cigarette-NRT 
users, fewer EC-only users were female; NRT-only users had started smoking the latest and EC-only users 
had the lowest proportion of family or friends who smoke. There was also considerable variation between 
groups in terms of ethnicity, marital status, cigarette consumption, recent illness and reported happiness levels 
(Table 2).
As previously reported, length of product use was broadly similar across group at around 17 months, 
and mean daily NRT and EC use, measured by self-reported nicotine dose, was higher for NRT-only and EC-
only users than for dual cigarette-NRT and cigarette-EC users (see (23) for details). In terms of the product 
type used, first generation ‘cig-a-likes’ with replaceable or disposable cartridges were most popular among 
dual cigarette-EC users (60.0%) and third/fourth generation advanced personal vaporisers most popular 
among EC-only users (47.2 %), with refillable pen-style, second generation EC equally popular among dual 
cigarette-EC (31.4%) and EC-only (36.1%) users. For both dual cigarette-NRT and NRT-only users, gum 
(44.4% and 33.3%, respectively) and patches (both 33.3%) were the most popular products, and a similar 
proportion (27.8%) used more than one NRT product.
a) Nicotine levels
Nicotine intake from different products was roughly comparable (Figure 1), although there was some 
variation across groups (Table S1). In terms of urinary biomarkers, users of all products had levels of total 
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nicotine equivalents at least as high as cigarette-only smokers in adjusted analysis (see Table 3). Findings in 
relation to salivary biomarkers varied. Dual cigarette-NRT users had relatively low nicotine and cotinine 
levels and EC-only users had relatively low nicotine levels, at around half that of cigarette-only users, with 
other groups obtaining levels slightly below or above those from cigarette-only users (Table 3). The minor 
tobacco alkaloids anabasine and anatabine which are specific to tobacco as opposed to nicotine exposure, 
clearly distinguished between smokers and ex-smokers, with significantly lower levels compared with 
cigarette-only, dual cigarette-NRT or cigarette-EC users (Table S1).
b) TSNA levels
There were clear differences in levels of the carcinogen metabolite NNAL (Figure 2). NRT-only and 
EC-only users had markedly lower levels than cigarette-only, dual cigarette-NRT and cigarette-EC users 
(p<0.001), with EC-only users having significantly lower levels than all other groups, at less than 3% of 
cigarette-only smoker levels (Table 3). Compared with cigarette-only smokers, there were no large 
differences in NNAL levels for dual cigarette-EC users but dual cigarette-NRT users had somewhat lower 
levels. Results followed a similar, albeit less pronounced, pattern for the other TSNAs measured (Table S1).
c) VOC levels
EC-only users had the lowest overall levels of the major urinary VOC metabolites, with acrylonitrile 
levels as low as 2.9% of cigarette-only smokers, and NRT-only users had the second lowest overall, with 
acrylonitrile levels as low as 10.5% of cigarette-only smokers (Table 3). By contrast, dual cigarette-NRT, 
cigarette-EC and cigarette-only users all had very similar VOC metabolite levels (Figure 2). Compared with 
all other groups, NRT-only and EC-only users at least halved the reference values of cigarette-only smokers 
(see Table 3), and had significantly lower levels of all major metabolites of selected toxicant and carcinogen 
VOCs (all p<0.001, Table S1).
Results were largely confirmed when looking at other VOC metabolites that were assessed, with EC-
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only users generally displaying the lowest levels, followed by NRT-only users and no detectable differences 
between dual cigarette-NRT, cigarette-EC and cigarette-only users (see Table S1). The only exceptions were 
metabolites of benzene (N-Acetyl-S-(phenyl)-L-cysteine (PMA) and muconic acid (MU)), carbon disulphide 
(2-thioxothiazolidine-4-carboxylic acid (TTCA)) and styrene (N-Acetyl-S-(1 and 2-phenyl-2-hydroxyethyl)-L-
cysteine (PHEMA) and phenylglyoxylic acid (PGA)). Dual cigarette-EC users had somewhat higher PMA, 
MU and PHEMA levels and dual cigarette-NRT and dual cigarette-EC users had somewhat higher PGA 
levels than other groups (Table S1). There were no appreciable group differences in TTCA levels. However, 
these metabolites were either non-specific to the parent VOC measured (MU, TTCA have dietary 
contributions, PGA is a metabolite of ethylbenzene and styrene exposure) or had low detection rates (PMA 
and PHEMA; see Table S2).
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Discussion
This is, to our knowledge, the first direct comparison of nicotine, important carcinogen and toxicant 
metabolite levels in long-term users of EC or NRT. We find that ex- smokers who had switched to exclusive 
EC or NRT use obtained roughly similar levels of nicotine compared with cigarette-only smokers, but results 
were variable. Exclusive use of NRT, and in particular of EC, but not dual use with cigarettes, was associated 
with lower levels of known tobacco-related carcinogens and toxicants measured in this study compared with 
cigarette-only use.
The finding that NRT-only or EC-only use is associated with roughly similar nicotine intake to 
cigarette-only use supports the view that users seek a particular level of nicotine intake, irrespective of the 
delivery system (49), and adjust product use accordingly (50). The finding is consistent with more recent (51)
but not older (8) studies on nicotine delivery from EC and may reflect the improved design of newer 
generations of EC products (52), highlighting the importance of focusing on experienced, long-term rather 
than naïve, short-term users. Similarly, efficient nicotine intake from exclusive NRT use has been observed in 
long-term (53) but not short and intermediate-term NRT users (54). The fact that intake was largely similar 
for both groups also suggests that better craving reductions observed in users of EC compared with NRT 
(23, 55) may be due to factors other than nicotine delivery, such as the greater behavioural similarity of EC 
use (as opposed to NRT use) with smoking. This is consistent with research on non-nicotine sensory factors 
that have been shown to influence tobacco withdrawal (56). However, it should be noted that this study was 
not powered to detect anything other than relatively large effects, so results are indeterminate regarding 
smaller differences in nicotine intake between these groups.
The lower carcinogen and toxicant levels associated with NRT-only and EC-only use in this study 
confirm the known low risk for long-term NRT product use (57). They also underscore the translation of 
greatly reduced concentrations of some carcinogens and toxicants from e-liquids and aerosol (4, 6, 58) to 
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body-level exposure, contrary to worries that long-term EC use would result in substantial harmful exposure 
(59). Given the involvement of these TSNAs and VOCs with cancer, cardiovascular and pulmonary diseases 
(e.g. 42, 60), these results suggest that complete substitution may result in reducing disease risk and supports 
the assertion that EC use may to be less harmful than smoking (2, 61-63). In this study, there was no 
evidence that long-term EC-only use is associated with greater carcinogen or toxicant levels than NRT-only 
use; if anything, on some measures it was associated with lower levels. While this could be due to occasional 
cigarette smoking lapses by long-term NRT-only users, this is unlikely to have made a substantial 
contribution given very low levels of tobacco-specific (as opposed to nicotine-specific) biomarkers for 
acrylonitrile, anabasine and anatabine (64, 65) in this group. Alternatively, these differences may reflect 
typical low-level contamination in these products (e.g. with nitrosamines from tobacco-derived nicotine (66)), 
non-specificity of the metabolite for the toxicant (e.g. muconic acid for benzene (67)), or non-smoking 
related environmental sources of toxicant exposure (e.g. for styrene (68)). Contrary to findings from a recent 
short-term switching study (12), dual cigarette-NRT or cigarette-EC use was not associated with appreciable 
reductions in carcinogen and toxicant levels. This may be because participants in the current study may have 
been even heavier smokers prior to starting concurrent EC or NRT use, thus masking the benefit of potential 
partial substitution in our cross-sectional study, or because dual users used non-combustible products to 
bridge times of non-smoking and thus did not actually reduce their cigarettes consumption. Alternatively, it 
may reflect either differences in study design, e.g. different usage pattern in long-term as opposed to short-
term users, or the relatively low power to detect smaller, yet meaningful, effects in this study. Further 
longitudinal research is needed to differentiate between these explanations.
The findings have several implications. While complete long-term switching to EC may produce a net 
benefit for the health outcomes of the smoking population, given the association with very low levels of 
dangerous constituents measured in this study similar in magnitude to NRT, it is only likely to be beneficial if 
complete cessation of cigarettes is achieved. Thus, dual users should be encouraged to cease using 
combustible products to reduce long-term health risks. Our results also indicate that machine-derived and 
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actual body-level exposure to toxicants can be very different as shown, for instance, by greatly reduced 
aldehyde levels in EC users here compared with reportedly high levels in EC aerosol under certain laboratory 
conditions ((5) but see (69)). Lastly, it should be noted that while exclusive EC and NRT use was associated 
with marked reductions in carcinogen and toxicant levels compared with cigarette-only smokers, it did not 
eliminate exposure (and thus possible health risks) completely. Full cessation of all nicotine products remains 
the best option to avoid harm.
The study had several limitations. Even though participants were recruited using diverse methods, 
resulting in a sample broadly similar to the population of NRT/EC users (16, 70), and we controlled for 
important confounders, group differences may not generalise and reflect self-selection. The sample was too 
small to allow more sophisticated analyses to evaluate the association of different types of EC or NRT (and 
other characteristics such as EC flavourings) with intake, and we may not have picked up small but important 
differences in exposure levels. In particular, the lack of group differences in nicotine intake has to be 
interpreted cautiously given the low power to detect smaller effects and the variability across different urinary 
and salivary measures. Lastly, we did not assess indirect exposure and the analysis was limited by the number 
of biomarkers available and spot sampling, which can only provide a snapshot of exposure. However, given
the lack of long-term data, we chose this pragmatic design to evaluate quickly potentially important 
associations of EC use with carcinogen and toxicant intake to inform further longitudinal work. Moreover, 
the relatively slow pharmacokinetics of the assessed metabolites (71) provides stable estimates of recent 
exposure and should militate against variations associated with different usage patterns of different products. 
Future work should attempt to sample a larger range of biomarkers over a longer period of time, including 
biomarkers of actual harm such as lung function measures, and evaluate the impact of potential interactions of 
user with device characteristics on delivery of toxicants to users and bystanders.
In conclusion, exclusive long-term NRT or EC use among ex-smokers is associated with substantially 
reduced levels of select carcinogens and toxicants compared with cigarette smoking; however, concurrent use 
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with cigarettes appears not to be. We found no evidence that EC-only compared with NRT-only use is 
associated with greater carcinogen and toxicant levels measured in this study. Nicotine delivery, though 
variable, is roughly comparably to cigarettes, but smaller meaningful differences may exist.
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Figure legends
Figure 1: ^Boxplots show median with interquartile range, IQR (25%-75%); error bars show Tukey’s 
whiskers and cross indicates arithmetic mean (geometric means are provided in Table S1); Solid grey circles 
show outliers; *Measured in urine: data are raw values divided by ratio of observed to covariate-adjusted 
creatinine levels; values below the limit of detection (LOD) were imputed by LOD divided by square root of 
2; †Measured in saliva; There were no significant differences between groups; NRT – Nicotine replacement 
therapy; EC – Electronic cigarette; Cig-Cigarette
Figure 2: ^Data are raw values divided by ratio of observed to covariate-adjusted creatinine levels; values 
below the limit of detection (LOD) were imputed by LOD divided by square root of 2; *Boxplots show 
median with interquartile range (25%-75%); error bars show Tukey’s whiskers and cross indicates arithmetic 
mean (geometric means are provided in Table S1); Solid grey circles show outliers; Significant pairwise 
comparisons are presented in Table S1; NRT – Nicotine replacement therapy; EC – Electronic cigarette; Cig-
Cigarette
26
Tables
Table 1: Major toxicants and carcinogens related to tobacco use
Parent compound Biomarker/Metabolite Rationale for inclusion
Tobacco-specific N-nitrosamines
4-(Methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK)
4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL)
A potent lung carcinogen (40)
and major contributor to cancer 
risk (34); Group 1 carcinogen 
(39); WHO Tobreg list: one out 
of nine toxicant recommended 
for mandated lowering in 
tobacco smoke (36)
Volatile organic compounds
Acrolein N-Acetyl-S-(3-hydroxypropyl)-L-
cysteine (3HPMA)
A major contributor to 
respiratory effects (34, 35); 
Group 3 carcinogen (41);WHO 
Tobreg list: one out of nine 
toxicant recommended for 
mandated lowering in tobacco 
smoke (36)
Acrylamide N-Acetyl-S-(2-carbamoylethyl)-
L-cysteine (AAMA)
Group 2A carcinogen (37); a 
neurotoxin (71)
Acrylonitrile N-Acetyl-S-(2-cyanoethyl)-L-
cysteine (CYMA)
A major contributor to cancer 
risk (34), highly specific VOC 
biomarker for tobacco use (33); 
Group 2B carcinogen (37); 
WHO Tobreg list: one out of 
nine toxicant considered high 
priority for disclosure and 
monitoring (36)
1,3-Butadiene N-Acetyl-S-(4-hydroxy-2-buten-
1-yl)-L-cysteine (MHBMA3)*
A major contributor to cancer 
risk (34, 35) ; Group 1 
carcinogen (42); WHO Tobreg 
list: one out of nine toxicant 
recommended for mandated 
lowering in tobacco smoke (36)
Ethylene Oxide N-Acetyl-S-(2-hydroxyethyl)-L-
cysteine (HEMA)†
Group 1 carcinogen (37)
*More selective metabolite of parent compound than N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA) (33); 
†Major urinary metabolite of ethylene oxide exposure, a minor metabolite of acrylonitrile and vinyl chloride exposure 
(toxic tobacco smoke constituents); WHO Tobreg -  World Health Organisation study group on tobacco product 
regulation; VOC – volatile organic compound; International Agency for Research on Cancer (IARC) classification of 
carcinogen groups: Group 1 - Carcinogenic to humans; Group 2A - Probably carcinogenic to humans; Group 2B - 
Possibly carcinogenic to humans; Group 3 - Not classifiable as to its carcinogenicity to humans; Group 4 - Probably not 
carcinogenic to humans
Characteristics
Total 
(N=181)
Smokers Ex-smokers P-value
Cigarette-
only
(N=37)
Dual 
cigarette-
NRT 
users
(n=36)
Dual 
cigarette-
EC users
(n=36)
NRT-
only 
users
(n=36)
EC-only 
users
(n=36)
Mean age (SD)
37.8 
(11.8)
34.4 
(14.0)
36.4 (8.5) 39.3 
(13.1)
40.3 
(11.1)
38.5 
(11.1)
0.27
% Female (N) 39.2 (71) 43.2 (16) 61.1 (22) 30.6 (11) 41.7 (15) 19.4 (7) 0.024
% White (N) 72.4 (131) 81.1 (30) 58.3 (21) 75.0 (27) 63.9 (23) 83.3 (30) 0.11
% High school 
(N)
77.3 (140) 67.6 (25) 83.3 (30) 80.6 (29) 77.8 (28) 77.8 (28) 0.61
% Single (N) 53.6 (97) 70.3 (26) 58.3 (21) 50.0 (18) 36.1 (13) 52.8 (19) 0.10
Mean age started 
smoking (SD)
17.8 (4.3) 16.6 (3.2) 18.2 (3.4) 17.3 (3.1) 20.3 
(6.4)
16.6 (3.2) 0.012
Mean cigarettes 
per day (SD)*
13.3 (8.7) 13.9 (9.0) 10.8 (4.6) 11.9 (9.6) 14.7 
(10.3)
15.9 (8.3) 0.10
Mean proportion 
of friends/family 
who smoke (SD)
35.6 
(27.5)
50.9 
(23.6)
39.8 
(24.1)
38.0 
(32.4)
33.2 
(27.7)
15.6 
(15.2)
<0.001
% Recent Illness 
(N)
23.2 (42) 37.8 (14) 8.3 (3) 19.4 (7) 27.8 (10) 22.2 (8) 0.10
Geometric mean 
salivary CRP 
levels, in μg/L 
(IQR)†
1.8 (2.5) 2.0 (3.4) 1.3 (1.1) 1.6 (3.5) 1.9 (2.1)‡ 2.2 (3.7) 0.86
Mean global life 
satisfaction (SD)§
3.9 (1.0) 4.1 (0.9) 3.8 (1.1) 3.7 (1.1) 3.9 (0.9) 3.9 (1.1) 0.60
Mean happiness 
levels (SD)‖
5.0 (1.5) 4.6 (1.7) 5.6 (1.1) 4.7 (1.7) 5.3 (1.3) 5.0 (1.6) 0.10
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Table 2: Socio-demographic, smoking, physical health and subjective well-being characteristics of study 
participants
†Statistical comparison conducted on log-transformed values (not shown); ‡N=1 missing; §Assessed by asking: “All 
things considered, how satisfied are you with your life as a whole?” with response options (1) “very dissatisfied” to (5) 
“very satisfied”; ‖Assessed by asking: “Some people are very generally very happy. They enjoy life regardless of what 
is going on, getting the most out of everything. To what extent does this characterisation describe you?” with response 
option from (1) “not at all” to (7) “a great deal”; NRT – nicotine replacement therapy; EC – electronic cigarette; CRP – 
C-reactive protein; IQR – interquartile range; P-value – omnibus test result, adjusted for the reported comparisons in 
this table using the false discovery rate (46)
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Table 3: Adjusted biomarker levels by group as proportion of cigarette-only smoker levels*
Parent Compound Biomarker/Metabolite Smokers Ex-smokers
Dual cigarette-
NRT users
(n=36)
Dual cigarette-EC 
users
(n=36)
NRT-only users
(n=36)
EC-only users
(n=36)
Alkaloids Percent (95% confidence interval)†
Nicotine Total nicotine equivalents† 104.2 (64.3-168.9) 156.8 (105.1-
233.8)
121.6 (62.5-236.8) 126.9 (82.1-196.2)
Nicotine‡ 64.2 (39.2-104.9) 152.2 (90.7-255.1) 135.1 (68.1-268.0) 60.4 (35.8-101.8)
Cotinine‡ 46.8 (26.3-83.3) 69.7 (42.1-115.3) 82.1 (42.9-157.3) 75.1 (45.3-124.4)
Tobacco Specific N-Nitrosamines 
4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK)
4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL)
57.1 (33.1-98.4) 81.2 (49.7-132.8) 11.6 (6.3-21.3) 2.5 (1.5-4.2)
Volatile Organic Compounds 
Acrolein N-Acetyl-S-(3-hydroxypropyl)-L-
cysteine (3HPMA)
107.1 (71.8-159.7) 91.2 (60.2-138.2) 35.3 (23.5-53.0) 33.3 (20.9-53.1)
Acrylamide N-Acetyl-S-(2-carbamoylethyl)-
L-cysteine (AAMA)
80.2 (57.9-111.1) 115.9 (80.8-166.1) 45.4 (32.4-63.5) 42.9 (31.1-59.2)
Acrylonitrile N-Acetyl-S-(2-cyanoethyl)-L-
cysteine (CYMA)
85.6 (48.7-150.4) 102.7 (63.7-165.6) 10.5 (5.4-20.6) 2.9 (1.7-4.7)
1,3-Butadiene N-Acetyl-S-(4-hydroxy-2-buten-
1-yl)-L-cysteine (MHBMA3)
101.9 (64.6-160.7) 115.0 (73.2-180.6) 19.9 (12.8-30.7) 11.0 (7.5-16.1)
Ethylene oxide, 
acrylonitrile, vinyl chloride
N-Acetyl-S-(2-hydroxyethyl)-L-
cysteine (HEMA)
86.6 (58.7-127.8) 104.0 (73.9-146.4) 54.2 (38.4-76.5) 43.5 (30.8-61.3)
*Levels as a proportion of cigarette-only smoker levels are estimated from a model that adjusted for all variables in Table 2, latency to product use and creatinine. For urinary 
metabolites, inputs to the model were divided by the ratio of observed to covariate-adjusted creatinine; †Sum of cotinine, nicotine, trans-3’-hydroxycotinine, cotinine N-oxide, 
nicotine 1’-oxide, norcotinine, nornicotine measured in urine; ‡Measured in saliva (all other metabolites measured in urine); NRT – nicotine replacement therapy; EC – electronic 
cigarette
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Supplementary Table S1: Urinary and saliva biomarker levels by group*
Parent Compound Biomarker/Metabolite Smokers Ex-smokers P-
value
Cigarette-only
(N=37)
Dual cigarette-
NRT users 
(n=36)
Dual cigarette-
EC users (n=36)
NRT-only users
(n=36)
EC-only users
(n=36)
Geometric mean (95% confidence interval)
Tobacco Alkaloids (saliva) ng/ml
Nicotine Nicotine‡ 260.3 (189.1-
358.4)
147.2 (102.1-
212.0)
299.4 (193.2-
464.0)
158.5 (97.1-
258.6)
184.4 (125.2-
271.6)
0.00
3†
Cotinine‡ 174.8 (105.1-
290.8)
67.1 (39.1-115.1) 149.2 (95.8-
232.3)
83.9 (45.8-153.7) 179.6 (118.1-
273.0)
0.13
4
Tobacco Alkaloids (urine) nmol or pmol/mg creatinine§
Nicotine Total nicotine equivalents‡ 21.1 (14.0-31.8) 8.5 (3.9-18.4) 28.8 (16.6-49.8) 6.3 (2.9-14.1) 25.0 (14.8-42.0) 0.20
4
trans-3’-Hydroxycotinine 8.5 (5.1-14.3) 3.2 (1.4-7.4) 10.9 (6-19.8) 2.8 (1.2-6.3) 11.4 (6.5-19.9) 0.44
2
Cotinine 5.9 (3.8-9.3) 1.8 (0.7-4.4) 8.2 (4.6-14.8) 1.4 (0.6-3.5) 7.5 (4.5-12.4) 0.18
8
Nicotine 1.9 (1.2-3.3) 1.2 (0.5-2.5) 4 (2.3-7.1) 0.8 (0.3-1.7) 2.5 (1.5-4.2) 0.08
8
Cotinine N-oxide 0.6 (0.4-1.0) 0.2 (0.1-0.5) 0.8 (0.5-1.4) 0.2 (0.1-0.4) 0.8 (0.5-1.3) 0.25
4
Nicotine 1’-oxide 0.7 (0.4-1.1) 0.4 (0.2-0.8) 1.3 (0.7-2.2) 0.2 (0.1-0.6) 0.9 (0.5-1.6) 0.16
6
Norcotinine 0.2 (0.1-0.3) 0.1 (0.1-0.2) 0.3 (0.2-0.5) 0.1 (0.1-0.1) 0.2 (0.1-0.3) 0.16
1
Nornicotine 0.2 (0.1-0.2) 0.1 (0.1-0.2) 0.2 (0.1-0.4) 0.1 (0.1-0.1) 0.1 (0.1-0.2) 0.02
2†
Anabasine Anabasine§ 17.0 (11.2-25.8)d,e 11.1 (6.3-19.4) 25.5 (16.3-40.1)d,e 5.5 (3.5-8.7)a,c 6.2 (4.1-9.5)a,c <0.0
01
Anatabine Anatabine§ 26.0 (16.3-41.4)d,e 14.9 (7.6-29.2)d 36.0 (22.0-59.1)d,e 3.8 (2.4-6.2)a,b,c 4.6 (2.8-7.6)a,c <0.0
01
Tobacco Specific N-Nitrosamines pg/mg creatinine
30
4-
(methylnitrosamino)-
1-(3-pyridyl)-1-
butanone (NNK)
4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL)‡
53.4 (36.6-77.8)d,e 24.4 (13.2-45.1)d,e 44.5 (28.5-69.4)d,e 4.83 (2.79-
8.34)a,b,c,e
1.47 (1.02-
2.12)a,b,c,d
<0.0
01
N’-nitrosoanabasine N’-nitrosoanabasine (NAB) 6.17 (4.31-8.82)d,e 3.64 (2.20-6.02)d,e 6.02 (4.15-8.73)d,e 1.52 (1.09-
2.12)a,b,c
1.07 (0.79-
1.47)a,b,c
<0.0
01
N’-nitrosoanatabine N’-nitrosoanatabine (NAT) 32.8 (20.5-52.5)d,e 11.8 (5.77-24.0)d,e 30.8 (18.5-51.1)d,e 2.95 (1.81-
4.81)a,b,c
1.79 (1.21-
2.67)a,b,c
<0.0
01
Volatile Organic Compounds ng/mg creatinine
Acrolein N-Acetyl-S-(2-carboxyethyl)-L-
cysteine (CEMA)
119.8 (88.2-
162.9)d,e
136.1 (100.7-
184)d,e
141.8 (106.7-
188.4)d,e
67.8 (49.3-
93.2)a,b,c
54.6 (41.7-
71.4)a,b,c
<0.0
01
N-Acetyl-S-(3-hydroxypropyl)-L-
cysteine (3HPMA)‡
488.4 (345.1-
691.2)d,e
499.7 (350-
713.5)d,e
574.5 (429.1-
769.2)d,e
236.1 (168.1-
331.6)a,b,c
175.3 (124-
247.8)a,b,c
<0.0
01
Acrylamide N-Acetyl-S-(2-carbamoylethyl)-L-
cysteine (AAMA)‡
65.6 (50.6-85.1)d,e 52.5 (40.4-68.4)d,e 82.4 (66.1-
102.8)d,e
33.6 (25.8-
43.7)a,b,c
29.3 (22.3-
38.3)a,b,c
<0.0
01
N-Acetyl-S-(2-carbamoyl-2-
hydroxyethyl)-L-cysteine 
(GAMA)
18.5 (14.7-23.3)d,e 16.8 (13.1-21.5) 24.3 (19.6-30.2)d,e 12.1 (9.5-15.5)
a,c 10.0 (7.6-13.2)a,c <0.0
01
Acrylonitrile N-Acetyl-S-(2-cyanoethyl)-L-
cysteine (CYMA)‡
49.2 (32.9-73.6)d,e 28.4 (15.6-51.9)d,e 51.6 (33.6-79.2)d,e 3.7 (2.1-6.5)
a,b,c 1.4 (1.1-1.9)a,b,c <0.0
01
Benzene trans,trans-Muconic acid (MU) 78.6 (58.2-106.2) 106.8 (72.7-
157.0)
135.0 (102.3-
178.1)e
131.8 (94.1-
184.5)
55.2 (42.3-71.9)c 0.00
2
N-Acetyl-S-(phenyl)-L-cysteine 
(PMA)
0.64 (0.48-0.84)c 0.44 (0.30-0.63)c 1.43 (1.11-
1.83)a,b,e
0.52 (0.37-0.71) 0.74 (0.55-0.98)c <0.0
01
1,3-Butadiene N-Acetyl-S-(3,4-dihydroxybutyl)-
L-cysteine (DHBMA)
202.7 (162.8-
252.3)e
204.3 (162.3-
257.3)e
294.9 (242.9-
358.0)e
204.2 (156.9-
265.9)
156.3 (126.0-
193.8)a,b,c
<0.0
01
N-Acetyl-S-(4-hydroxy-2-buten-1-
yl)-L-cysteine (MHBMA3)‡
29.8 (19.9-44.8)d,e 23.9 (15.1-37.9)d,e 36.6 (25.4-52.6)d,e 7.67 (5.08-
11.6)a,b,c
4.44 (3.42-
5.78)a,b,c
<0.0
01
Carbon disulfide 2-Thioxothiazolidine-4-
carboxylic acid (TTCA)
6.03 (4.40-8.27) 13.8 (8.79-21.7) 9.95 (6.85-14.5) 13.4 (9.07-19.7) 6.84 (4.33-10.8) 0.01
5†
Crotonaldehyde N-Acetyl-S-(3-hydroxypropyl-1-
methyl)-L-cysteine (HPMMA)
804.2 (563.8-
1147.1)d,e
735.3 (495.2-
1091.7)d,e
1199.5 (881.9-
1631.6)d,e
366.3 (266.0-
504.5)a,b,c
235.9 (179.1-
310.7)a,b,c
<0.0
01
Cyanide 2-Aminothiazoline-4-carboxylic 
acid (ATCA)
91.2 (69.6-119.5)e 107.1 (79.4-
144.5)d,e
132.3 (97.8-
179.0)d,e
102.0 (72.6-
143.4)
55.3 (41.0-
74.5)a,b,c
0.01
3
N,N-
Dimethylformamide
N-Acetyl-S-(N-methylcarbamoyl)-
L-cysteine (AMCC)
162.2 (120.6-
218.1)e
138.5 (95.4-
201.2)e
176.3 (129.1-
240.5)e
100.2 (72.4-
138.7)
60.8 (44.4-
83.3)a,b,c
<0.0
01
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Ethylene oxide, 
acrylonitrile, vinyl 
chloride
N-Acetyl-S-(2-hydroxyethyl)-L-
cysteine (HEMA)‡
0.81 (0.61-1.07)d,e 0.81 (0.55-1.18) 1.15 (0.84-1.57)d,e 0.64 (0.48-0.84)
a,c 0.42 (0.32-
0.55)a,b,c
<0.0
01
Propylene oxide N-Acetyl-S-(2-hydroxypropyl)-L-
cysteine (2HPMA)
41.1 (30.4-55.6)e 47.3 (35.6-63.0)e 68.9 (52.6-90.4)d,e 37.4 (28.7-48.9)
c 29.3 (21.9-
39.3)a,b,c
<0.0
01
Styrene Mandelic acid (MA) 188.6 (147.4-
241.2)e
198.7 (153.8-
256.7)e
227.2 (181.1-
284.9)e
173.0 (127.3-
235.3)
100.8 (78.2-
129.9)a,b,c
<0.0
01
N-Acetyl-S-(1 and 2-phenyl-2-
hydroxyethyl)-L-cysteine 
(PHEMA)
0.75 (0.57-0.98) 0.82 (0.56-1.18) 1.09 (0.8-1.48)e 0.75 (0.55-1.00) 0.48 (0.36-0.63)
c 0.00
1
Styrene, 
ethylbenzene
Phenylglyoxylic acid (PGA) 88.0 (62.6-123.8) 129.9 (92.1-
183.3)e
124.5 (91.1-
170.0)
88.1 (60.6-128.2) 71.1 (53.7-94.1)b 0.00
7
Xylene 2-Methylhippuric acid (2MHA) 41.9 (30.1-58.4)d,e 36.3 (23.9-55.2)d,e 56.9 (41.8-77.4)d,e 19.6 (13-29.7)
a,b,c 10.5 (7.80-14.2) <0.0
01
3- + 4-Methylhippuric acids 
(34MHA)
266.5 (182.1-
390.1)d,e
181.1 (119.7-
274.0)d,e
273.2 (201.1-
371.0)d,e
76.3 (48.8-
119.4)a,b,c
51.4 (38.5-
68.6)a,b,c
<0.0
01
*Data presented are log-transformed raw values (for urinary metabolites also standardized for creatinine). Statistical comparisons were carried out on non-transformed data, adjusted for all 
variables in Table 2, latency to product use and creatinine; †Overall differences but no significant (Sidak-corrected) difference in post-hoc test; ‡Non-log transformed data shown in Figures 1 
and 2; §Indicates pmol/mg creatinine;
a, b, c, d, e 
indicates statistically significant (Sidak-corrected) difference (p<0.05) (a) cigarette-only smokers, (b) dual cigarette-NRT users, (c) dual cigarette-
EC users, (d) NRT-only users, and (e) EC-only users; NRT – nicotine replacement therapy; EC – electronic cigarette; P-value – omnibus test result, adjusted for the number of reported 
comparisons in this table using the false discovery rate (46)
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Supplementary Table S2: Proportion of samples below limit of detection by group and across all samples
Biomarker/Metabolite* Limit of 
detection
All samples Smokers Ex-smokers
Cigarette-
only
(N=37)
Dual 
cigarette-
NRT users
(n=36)
Dual 
cigarette-
EC users
(n=36)
NRT-only 
users (n=36)
EC-only 
users
(n=36)
Percent
Nicotine† 10 ng/mL 1.1 0.0 0.0 2.8 2.8 0.0
Cotinine† 10 ng/mL 14.4 13.5 16.7 5.6 27.8 8.3
trans-3’-Hydroxycotinine 0.03 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
Cotinine 0.03 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
Nicotine 10.5 ng/mL 11.0 2.7 13.9 5.6 30.6 2.8
Cotinine N-oxide 2 ng/mL 7.7 0.0 13.9 2.8 19.4 2.8
Nicotine 1’-oxide 2.5 ng/mL 8.8 0.0 13.9 2.8 25.0 2.8
Norcotinine 2.5 ng/mL 11.6 0.0 22.2 5.6 27.8 2.8
Nornicotine 1.1 ng/mL 17.7 5.4 30.6 11.1 33.3 8.3
Anabasine 0.5 ng/mL 29.3 10.8 36.1 13.9 55.6 30.6
Anatabine 0.4 ng/mL 29.3 5.4 27.8 11.1 61.1 41.7
N-Acetyl-S-(2-carboxyethyl)-L-
cysteine (CEMA)
8 ng/mL 2.8 0.0 2.8 0.0 5.6 5.6
N-Acetyl-S-(3-hydroxypropyl)-L-
cysteine (3HPMA)
13 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
N-Acetyl-S-(2-carbamoylethyl)-L-
cysteine (AAMA)
2.2 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
N-Acetyl-S-(2-carbamoyl-2-
hydroxyethyl)-L-cysteine (GAMA)
9.4 ng/mL 30.9 16.2 25.0 19.4 41.7 52.8
N-Acetyl-S-(2-cyanoethyl)-L-
cysteine (CYMA)
0.5 ng/mL 2.2 0.0 0.0 0.0 2.8 8.3
trans,trans-Muconic acid (MU) 20 ng/mL 6.6 2.7 2.8 2.8 5.6 19.4
N-Acetyl-S-(phenyl)-L-cysteine 
(PMA)
0.6 ng/mL 56.9 37.8 94.4 30.6 86.1 36.1
33
N-Acetyl-S-(3,4-dihydroxybutyl)-L-
cysteine (DHBMA)
5 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
N-Acetyl-S-(4-hydroxy-2-buten-1-
yl)-L-cysteine (MHBMA3)
0.6 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
2-Thioxothiazolidine-4-carboxylic 
acid (TTCA)
3.5 ng/mL 28.2 29.7 22.2 41.7 13.9 33.3
N-Acetyl-S-(3-hydroxypropyl-1-
methyl)-L-cysteine (HPMMA)
2 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
2-Aminothiazoline-4-carboxylic 
acid (ATCA)
15 ng/mL 7.2 0.0 8.3 5.6 5.6 16.7
N-Acetyl-S-(N-methylcarbamoyl)-L-
cysteine (AMCC)
5.5 ng/mL 0.6 0.0 0.0 2.8 0.0 0.0
N-Acetyl-S-(2-hydroxyethyl)-L-
cysteine (HEMA)
0.6 ng/mL 48.6 32.4 41.7 27.8 61.1 80.6
N-Acetyl-S-(2-hydroxypropyl)-L-
cysteine (2HPMA)
1.3 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
Mandelic acid (MA) 12 ng/mL 1.1 0.0 0.0 0.0 2.8 2.8
N-Acetyl-S-(1 and 2-phenyl-2-
hydroxyethyl)-L-cysteine (PHEMA)
0.7 ng/mL 61.3 48.6 58.3 55.6 63.9 80.6
Phenylglyoxylic acid (PGA) 12 ng/mL 9.9 10.8 11.1 8.3 11.1 8.3
2-Methylhippuric acid (2MHA) 5 ng/mL 0.0 0.0 0.0 0.0 0.0 0.0
3- + 4-Methylhippuric acids 
(34MHA)
8 ng/mL 1.7 0.0 0.0 0.0 2.8 5.6
4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL)
0.6 pg/mL 6.6 0.0 2.8 0.0 8.3 22.2
N’-nitrosoanabasine (NAB) 4.0 pg/mL 47.0 8.1 38.9 25.0 80.6 83.3
N’-nitrosoanatabine (NAT) 1.6 pg/mL 43.1 5.4 41.7 13.9 75.0 80.6
*Urinary biomarkers, unless where indicated; †Measured in saliva
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